Drug Discovery Today

MAY 4, 2023

London, UK, 3rd May 2023 / The RSA Group, a leading life sciences executive search firm, has published the latest of its Talent Equity® Reports: No turning back – an analysis of the hybrid working models that have emerged from the pandemic and how they have enabled positive changes to leadership, team dynamics and recruitment and retention of talent in the life science sector.

Science 113

Science 113

ASPET

MAY 4, 2023

Drug biliary clearance (CL bile ) in vivo is among the most difficult pharmacokinetic parameters to predict accurately and quantitatively because biliary excretion is influenced by metabolic enzymes, transporters, and passive diffusion across hepatocyte membranes. The purpose of this study is to demonstrate the use of Hu-FRG{trade mark, serif} mice (Fah –/– /Rag2 –/– /Il2rg –/– [FRG] mice transplanted with human-derived hepatocytes) to quantitatively predict h

Pharmacokinetics 100

Pharmacokinetics Drugs 100

Chemical Biology and Drug Design

MAY 1, 2023

We found overexpression of C-FLIPS, MCL-1, and survivin by SphK2 silencing has an effective important modality to enhance cell sensitivity to paclitaxel via the induction of apoptosis in colon cancer cells. Abstract The sphingosine kinase-2 (SphK2), a main component of sphingolipid signal transduction, is reported as an innovative therapeutic candidate for cancer treatment.

Treatment 100

Treatment Research 100

Antidote

MAY 3, 2023

Every May is dedicated to Skin Cancer Awareness Month — a national observance designed to raise awareness around skin cancer and encourage people to practice smart prevention tactics as spring transitions into summer. Though skin cancer is the most common type of cancer , forming good sun safety habits can have a direct link to a reduction in its prevalence.

98

98

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Drug Patent Watch

APRIL 30, 2023

Annual Drug Patent Expirations for AGGRASTAT Aggrastat is a drug marketed by Medicure and is included in two NDAs. It is available from one supplier. There is one patent protecting… The post New patent expiration for Medicure drug AGGRASTAT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 76

Drugs Marketing 76

Drug Channels

MAY 2, 2023

In my most recent video webinar , I explored how the rapid expansion of patient-paid prescriptions—via cash-pay pharmacies and discount card vendors—is transforming the prescription market. Below, I follow the dollar when a patient uses a discount card to pay for a generic drug prescription. As you’ll see, a discount card can save money for consumers by leveraging several quirks of U.S. retail pharmacy pricing.

Pharmacy 73

Pharmacy Drugs Marketing 73

FDA Law Blog: Drug Discovery

MAY 4, 2023

By McKenzie E. Cato — On May 2nd, FDA released a new draft guidance with recommendations for decentralized clinical trials (DCTs) for drugs, biologics, and devices. A DCT is a clinical trial where some or all of the trial-related activities, such as administration of the investigational product, data collection, or safety monitoring, occur at locations other than traditional clinical trial sites.

Clinical Trials 59

Clinical Trials Trials FDA Production 59

Drug Patent Watch

MAY 2, 2023

This chart shows the patent expirations for capsule dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from… The post Capsule dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 74

Drugs 74

FDA Law Blog: Biosimilars

MAY 3, 2023

By Deborah L. Livornese — FDA posted the last five “deemed final orders” under OTC monograph reform this week. All 33 of the final orders can now be found at OTCMONOGRAPHS@FDA. Under the 2020 Coronavirus Aid, Relief, and Economic Security Act (CARES Act) (see our blog post here ), all final monographs (i.e., the regulations formerly found in 21 C.F.R. parts 331 through 358) were deemed to be final administrative orders as of the CARES Act effective date.

FDA 57

FDA Regulations Production Drugs 57

Cytel

MAY 5, 2023

As clinical trials become more complex, simulation-guided design approaches are crucial. For this edition of the Industry Voices series, Cytel’s Chief Product Officer & General Manager Scott Gaines discusses how simulation-guided design and Cytel’s Solara® clinical strategy platform have evolved clinical development strategy, enabling sponsors to select optimal designs even as clinical trials involve more study objectives and more sophisticated decision rules, and to better focus on strategi

Clinical Trials 52

Clinical Trials Trials Clinical Development Production 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

The Premier Consulting Blog

MAY 4, 2023

The global ophthalmic drugs market size was valued at $33.81 billion in 2022 and is expected to grow approximately eight percent from 2023 to 2030 [1]. Given this trend, many biopharmaceutical companies are investing in strategies to develop and commercialize new or existing ophthalmic products that address unmet medical needs. Now, these companies are required to comply with new guidance from the U.S.

FDA 52

FDA Packaging Compliance Regulations 52

Drug Patent Watch

MAY 5, 2023

This chart shows the pharmaceutical companies with the most aerosol dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most aerosol dosed drugs… The post Which pharmaceutical companies have the most aerosol dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs 52

FDA Law Blog: Biosimilars

APRIL 30, 2023

By Kurt R. Karst & Michael D. Shumsky — On May 2nd, the U.S. Senate Committee on Health, Education, Labor and Pensions (“Senate HELP”) is scheduled to take up legislation that could significantly limit access to the courts and immunize critical FDA decisions from timely judicial review. That bill is S. 1067, the “ Ensuring Timely Access to Generics Act of 2023 ,” and it would fundamentally transform the playing field for NDA, ANDA, BLA, and aBLA applicants seeking to preserve their rights i

FDA 57

FDA Biosimilars Regulations FDA Approval 57

Reprocell

MAY 5, 2023

Members of the UK Parliament were impressed and somewhat surprised recently by an exchange between the Prime Minister and the leader of the opposition during Prime Minister’s questions. 1 The opponents exchanged polite introductions and proceeded to debate the issues of the day in a calm and thoughtful manner, without raising their voice. The members were in fact watching an exchange with an AI chatbot, programmed to answer questions of the type often raised in the weekly shouting match.

Drugs 52

Drugs 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Drug Target Review

MAY 5, 2023

Personalised Precision Medicine (PPM) relies heavily on the use of data and artificial intelligence (AI) to tailor treatment plans to an individual’s unique biomarkers , predict their reaction to certain treatments, and target diseases based on their genetic makeup or environmental factors. While PPM holds great promise for improving patient outcomes, it also faces challenges such as data management, security and the escalating costs of research and development.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

Drug Patent Watch

MAY 5, 2023

Annual Drug Patent Expirations for PROAIR+DIGIHALER Proair Digihaler is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from one supplier. There are… The post New patent expiration for Teva Branded drug PROAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Antidote

MAY 5, 2023

Patient Experience Week is a designated time to acknowledge the healthcare staff that influence the patient experience every single day. From doctors and nurses to site staff and research coordinators, there are many individuals in the healthcare industry who make a difference in the lives of patients.

Nurses 52

Nurses Doctors Research 52

Drug Channels

MAY 4, 2023

Today’s guest post comes from Justin Smerker, VP of Business Development at RareMed Solutions. Justin introduces us to RareMed Solutions, a patient service provider that caters to patients with complex and rare diseases. To learn about RareMed and their approach to the delivery of patient services for complex or rare conditions, visit www.raremed.com or email info@raremed.com.

Disease 52

Disease Drugs 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

PLOS: DNA Science

MAY 4, 2023

Dense living communities of hundreds of bacterial species form biofilms on our teeth. Without careful brushing and flossing of this dental plaque, minerals seep in, hardening it into tartar. When proteins in saliva adhere tartar to tooth surfaces, a trip to the dentist is required to hack the stuff off. Over time, the mineralized microbes of tooth tartar come to comprise a mouthful of tiny fossils, including snippets of degraded bacterial DNA.

DNA 52

DNA Production RNA Science 52

Drug Patent Watch

MAY 5, 2023

Annual Drug Patent Expirations for PROAIR+RESPICLICK Proair Respiclick is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from one supplier. There are… The post New patent expiration for Teva Branded drug PROAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

H1 Blog

MAY 4, 2023

Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education. With the rise of digital technology, pharma can now identify and engage a new generation of health care professionals (HCPs) who are leveraging social media to become influential digital opinion leaders.

Pharmaceutical Companies 52

Pharmaceutical Companies Clinical Research Pharma Companies Pharmaceuticals 52

Covalent Modifiers

MAY 3, 2023

Mahía, Alejandro , Kiib, Anders , Nisavíc, Marija , Svenningsen, Esben , Palmfeldt, Johan , Poulsen, Thomas Bjørnskov , Angew. Chem. Int. Ed. 2023 , e202304142 [link] Electrophilic groups are one of the key pillars of contemporary chemical biology and medicinal chemistry. For instance, the group of 3-membered N-heterocyclic compounds – such as aziridines, azirines, and oxaziridines – possess unique electronic and structural properties which underlie their potential and applicability as covalent

52

52

addgene Blog

MAY 4, 2023

The biomedical field is often concerned with understanding the cause of diseases and how to treat those diseases. The “cause of disease” often requires understanding the disease genetics and the “treatment” usually requires drugs. While we often think of these two fields as separate, they are deeply intertwined. In this blog we will review how CRISPR technology has brought drug and genetic screens together and expedited the drug discovery pipeline.

Drugs 52

Drugs Disease Treatment 52

Drug Patent Watch

MAY 5, 2023

Annual Drug Patent Expirations for BONIVA Boniva is a drug marketed by Roche and Hoffmann La Roche and is included in two NDAs. It is available from one supplier. There… The post New patent expiration for Hoffmann La drug BONIVA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

DS in Pharmatics

MAY 4, 2023

Diagnosing illnesses and monitoring health is increasingly reliant on utilizing software. For patients, manufacturers must maintain standards and regulations. Companies can be concerned with challenges concerning updated legislation such as the EU’s MDR.

Compliance 52

Compliance Regulations 52

Drug Target Review

MAY 4, 2023

A new approach developed by researchers at New York University (NYU) and the New York Genome Centre, US, combines genetic association studies, gene editing, and single-cell sequencing to address human genetic challenges and discover causal variants and genetic mechanisms for blood cell traits. Their approach, dubbed STING-seq, published in Science , addresses the challenge of directly connecting genetic variants to human traits and health, and can help scientists identify drug targets for diseas

Disease 52

Disease Small Molecule Protein Expression Research 52

Tecan

MAY 4, 2023

By Magali Wolff You could say that the road to in vitro diagnostic medical devices regulation (IVDR) implementation has been rocky. We have read all of the documents, spent hours in meetings and felt our heart stop with every new announcement about the new regulations.

Laboratories 52

Laboratories Regulations Compliance Science 52

Drug Patent Watch

MAY 5, 2023

Annual Drug Patent Expirations for ORLADEYO Orladeyo is a drug marketed by Biocryst and is included in one NDA. It is available from one supplier. There are six patents protecting… The post New patent for Biocryst drug ORLADEYO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

ACTO

MAY 4, 2023

Most people in the training world have heard of Ebbinghaus’ Forgetting Curve and The Learning Pyramid. According to the Forgetting Curve, most learners forget 50% of what they’ve learned after only 20 minutes and 90% of knowledge is forgotten within a week. However, The Learning Pyramid suggests that if learners apply the information, they can retain up to 90% of it.

Science 52

Science Marketing Research Production 52

Cytel

MAY 3, 2023

With input by Alind Gupta, Louis Dron, and Jason Simeone. Randomized clinical trials (RCTs) have long been considered the gold standard for assessing the efficacy of medical treatments, but real-world evidence (RWE) is often more representative of routine clinical care. The RCT DUPLICATE study makes great strides in comparing the two, but the study has its limitations: notably, the lack of quantitative bias analysis.

Clinical Trials 52

Clinical Trials Trials Treatment 52

Metabolite Tales Blog

MAY 3, 2023

Hypha’s Q2 2023 Newsletter – acyl glucuronides, hydroxylated metabolites and our latest blogs In our Q2 2023 newsletter we look at the synthesis of a prominent acyl glucuronide of the Mcl-1 inhibitor AZD5991, hydroxylated metabolites of the recently FDA approved rezafungin, as well as links to our latest blogs. Sign up at the bottom of the page in the link here to receive our quarterly newsletter by email.

FDA Approval 52

FDA Approval FDA 52

Drug Patent Watch

MAY 4, 2023

Expiring drug patents are continuously driving innovation, as branded firms seek out new high-margin opportunities. Examining the patent expirations by year can indicate which pharmaceutical companies face the most peril… The post Drugs facing the most patent expirations this year appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Drugs Pharmaceuticals 52

Practical Cheminformatics

MAY 2, 2023

While machine learning (ML) models have become integral to many drug discovery efforts, most of these models are "black boxes" that don't explain their predictions. There are several reasons we would like to be able to explain a prediction. Provide scientific insights that will guide the design of new compounds. Instill confidence among team members.

Drugs 52

Drugs 52